Image 2_Load-bearing aerobic exercise prior to injury moderates systemic immunosuppression response to fracture.jpeg by Lia K. Strait (22229095)

“…Subjects that exercised before fracture had decreased post-fracture circulating immunosuppressive myeloid-derived suppressor cells and pain sensitivity, however there was no significant effect of prehabilitation on bone repair volume, defect bridging rate, or biomechanical properties. …”

Table 1_Load-bearing aerobic exercise prior to injury moderates systemic immunosuppression response to fracture.docx by Lia K. Strait (22229095)

“…Subjects that exercised before fracture had decreased post-fracture circulating immunosuppressive myeloid-derived suppressor cells and pain sensitivity, however there was no significant effect of prehabilitation on bone repair volume, defect bridging rate, or biomechanical properties. …”

Table 2_Load-bearing aerobic exercise prior to injury moderates systemic immunosuppression response to fracture.docx by Lia K. Strait (22229095)

“…Subjects that exercised before fracture had decreased post-fracture circulating immunosuppressive myeloid-derived suppressor cells and pain sensitivity, however there was no significant effect of prehabilitation on bone repair volume, defect bridging rate, or biomechanical properties. …”

Image 1_Load-bearing aerobic exercise prior to injury moderates systemic immunosuppression response to fracture.jpeg by Lia K. Strait (22229095)

“…Subjects that exercised before fracture had decreased post-fracture circulating immunosuppressive myeloid-derived suppressor cells and pain sensitivity, however there was no significant effect of prehabilitation on bone repair volume, defect bridging rate, or biomechanical properties. …”

Species removal dampens the scale dependency of ecological determinism and stochasticity in rocky intertidal communities [dataset and codes] by Nelson Valdivia (600515)

“…However, the responses of both processes to the loss of foundation species, which strongly influence community dynamics across spatial scales, are unclear. We experimentally examined how spatial extent and foundation species removal affect rocky-intertidal community dynamics over three years in eight field sites spanning ~1000 km along the southeastern Pacific. …”

Table1_Intranasal dexmedetomidine sedation for EEG in children with autism spectrum disorder.xlsx by Arianna De Laurentiis (19829892)

“…Clinical, EEG, and sedation data were stored in a database. A logistic multiple regression model was employed, with the failure of EEG serving as the dependent variable.…”

Data Sheet 1_Comprehensive analysis on the regulatory mechanism of active ingredient accumulation during fermentation process of Massa Medicata Fermentata: microbe and metabolic pr... by Yun Li (692280)

“…</p>Results<p>During the fermentation process, bacterial diversity generally shows an increasing trend, whereas fungal diversity generally shows a decreasing trend. Revealing that the differentially abundant metabolites were primarily categorized into lipids, amino acids and derivatives, phenolic acids, organic acids, flavonoids, lignans and coumarins, nucleotides and derivatives, and alkaloids. …”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”

DataSheet1_Mineral nutrition for Cannabis sativa in the vegetative stage using response surface analysis.docx by Patrick Yawo Kpai (20376234)

“…<p>Cannabis cultivated for medical and adult use is a high-value horticultural crop in North America; however, we lack information on its optimal mineral nutrition due to previous legal restrictions. …”